Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Irving Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:ChemotherapyHospital:Irving Cancer Center
Drugs:Journal:Link
Date:Dec 2008

Description:

Patients: This phase 2 study involved 40 women with recurrent primary peritoneal or epithelial ovarian cancer. The median age was 58, ranging from 30 to 82 years of age.

Treatment: Patients were treated with the chemotherapy drugs topotecan and navelbine (vinorelbine).

Toxicity: Grade 4 abnormal white blood cell counts, neutropenia, anemia, and febrile neutropenia were reported (in 20% or fewer patients). Grade 3 toxicities included abnormal cell counts, febrile neutropenia, gastrointestinal upset, fatigue, pain, and thromboembolism.

Results: The median overall survival was 16.4 months.

Support: Researchers doing this study have received money (less than $10,000 each) from GlaxoSmithKline, which markets topotecan as Hycamtin and vinorelbine as Navelbine.

Correspondence: Dr. Thomas J. Herzog



Back